跳至主要内容
临床试验/JPRN-UMIN000027441
JPRN-UMIN000027441已完成未知

The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1) - Hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

Osaka University0 个研究点目标入组 10 人开始时间: 2017年5月23日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)Patients who could not resected curatively.(2)Patients with active double cancer. (3)Patients with serious drug hypersensitivity or with a history of drug allergy.(4)Patients with serious complications.(5)Patients with jaundice,cirrhosis or with suspected cirrhosis of the liver.(6)There is a history of chronic hepatitis B, and in the present study drug has already been ingested.(7)Patients with active infection.(8)Women who have a possibility of or in the pregnancy,who hope to become pregnant,or who are breast-feeding. Men who wish to become pregnant partner.(9)Patients with severe mental disorder.(10)Other patients whom the physician decided to be unsuitable for safely carrying out the present study.

研究者

相似试验